What are the primary adverse effects (AEs) associated with cyclophosphamide?

Cyclophosphamide is a chemotherapy agent widely used in treating various malignancies, and its primary adverse effects include myelosuppression and nausea/vomiting. Myelosuppression refers to the decrease in bone marrow activity, which can lead to reductions in red blood cells, white blood cells, and platelets, resulting in anemia, increased infection risk, and bleeding complications. Nausea and vomiting are common side effects of many chemotherapeutic agents, including cyclophosphamide, due to their effect on the gastrointestinal tract and the brain's vomiting center.

In clinical practice, monitoring for these adverse effects is essential, as they significantly impact patient quality of life and treatment tolerability. Awareness and management of these side effects improve overall patient outcomes during chemotherapy. The other options provided focus on adverse effects that are either less common with cyclophosphamide or related to different drugs or classes of drugs within oncology treatments.